Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Exclusion Criteria17

• Recipients of second allogeneic stem cell transplant.
• Acute GVHD induced by donor lymphocyte infusion, interferon.
• Received first line aGVHD treatment before enrollment.
• Overlap GVHD syndrome.
• Pregnant or breast-feeding women.
• Pregnant or breast-feeding women.
• Serum creatinine \> 2.0 mg/dL or creatinine clearance \< 40 mL/min measured or calculated by Cockroft-Gault equation.
• Uncontrolled infection.
• Human immunodeficiency virus infection.
• Active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.
• Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.
• Allergic history to Janus kinase inhibitors.
• Severe organ dysfunction unrelated to underlying GVHD, including:
• (1)Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).
• (2)Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.
• (3)Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.
• Received Janus kinase inhibitor therapy after allo-HSCT for any indication. 15.Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.